scholarly journals Bone age in prepubertal children with nonfamilial or familial idiopathic short stature and prepubertal short-stature children born small for gestational age: a longitudinal data analysis

2021 ◽  
Vol 30 (4) ◽  
pp. 171-177
Author(s):  
Mari Satoh
Keyword(s):  
Data Analysis ◽  
Longitudinal Data ◽  
Short Stature ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Longitudinal Data Analysis ◽  
Bone Age ◽  
Idiopathic Short Stature ◽  
Prepubertal Children

scholarly journals Delayed Bone Age Might Accelerate the Response to Human Growth Hormone Treatment in Small for Gestational Age Children with Short Stature

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Jung-Eun Moon ◽  
Cheol Woo Ko
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Human Growth ◽  
Bone Age ◽  
Pediatric Endocrinology ◽  
Gh Therapy ◽  
Gh Treatment ◽  
The Impact

Purpose. Growth hormone (GH) treatment is recommended to improve growth and psychosocial problems in short stature children born small for gestational age (SGA). Although GH therapy in these patients has been extensively studied, the impact of therapy according to delays in bone age (BA) is not known well. Objective. To investigate the effects of GH therapy in SGA patients with short stature according to BA delay. Methods. We retrospectively analyzed changes in height SD score (SDS) and BA/chronological age (CA) after 6 and 12 months of GH therapy in patients grouped according to BA delay. We studied 27 SGA children with short stature in the pediatric endocrinology clinic of Kyungpook National University Children’s Hospital. Results. Of the 27 patients, 9 had <2 years of BA delay, while 18 had >2 years of delay. There were no significant differences between the two groups in terms of gestational age and weight at birth, height SDS, IGF-1 SDS, and growth hormone dosage at the beginning of therapy. However, height SDS increased significantly in the group with >2 years of BA delay after 6 months of GH therapy (−2.50 ± 0.61 vs −1.87 ± 0.82; p=0.037) and 12 months (−2.27 ± 0.70 vs −1.63 ± 0.65; p=0.002). When height SDS was compared between with and without GHD, there were no significant differences. Conclusions. Delayed BA (>2 years) may impact the response to GH treatment in SGA children with short stature.

scholarly journals Prevalence of IGF1 deficiency in prepubertal children with isolated short stature

2009 ◽  
Vol 161 (1) ◽  
pp. 43-50 ◽  
Author(s):  
T Edouard ◽  
S Grünenwald ◽  
I Gennero ◽  
J P Salles ◽  
M Tauber
Keyword(s):  
Short Stature ◽  
Gestational Age ◽  
Bone Age ◽  
Pediatric Endocrinology ◽  
Exclusion Criteria ◽  
Prepubertal Children ◽  
Gh Secretion ◽  
Appropriate For Gestational Age ◽  
Low Levels ◽  
Igf1 Deficiency

Background/aims‘Primary IGF1 deficiency (IGFD)’ is defined by low levels of IGF1 without a concomitant impairment in GH secretion in the absence of secondary cause. The aims of this study were to evaluate the prevalence of non-GH deficient IGFD in prepubertal children with isolated short stature (SS) and to describe this population.MethodsThis retrospective study included all children with isolated SS seen in our Pediatric Endocrinology Unit from January 2005 to December 2007. Children were included based on the following criteria: i) SS with current height SDS ≤ −2.5, ii) age≥2 years, and iii) prepubertal status. Exclusion criteria were: i) identified cause of SS and ii) current or past therapy with rhGH. IGF1-deficient children were defined as children without GH deficiency and with IGF1 levels below or equal to −2 SDS.ResultsAmong 65 children with isolated SS, 13 (20%) had low IGF1 levels, consistent with a diagnosis of primary IGFD, four of which were born small for gestational age and nine were born appropriate for gestational age. When compared with non-IGFD children, IGFD children had higher birth weight (−0.7 vs −1 SDS, P=0.02) and birth height (−1.7 vs −2 SDS, P=0.04) and more delayed bone age (2.6 vs 1.7 years, P=0.03).ConclusionThe prevalence of primary IGFD was 20% in children with isolated SS. Concerning the pathophysiology, our study emphasizes that IGFD in some children may be secondary to nutritional deficiency or to maturational delay.

IGF1, IGF1R and SHOX Mutation Analysis in Short Children Born Small for Gestational Age and Short Children with Normal Birth Size (Idiopathic Short Stature)

2012 ◽  
Vol 77 (4) ◽  
pp. 250-260 ◽  
Author(s):  
Janina Caliebe ◽  
Sander Broekman ◽  
Merel Boogaard ◽  
Cathy A.J. Bosch ◽  
Claudia A.L. Ruivenkamp ◽  
...  
Keyword(s):  
Short Stature ◽  
Mutation Analysis ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Idiopathic Short Stature ◽  
Birth Size ◽  
Normal Birth ◽  
Short Children

scholarly journals Unexpected high frequency of skeletal dysplasia in idiopathic short stature and small for gestational age patients

2014 ◽  
Vol 170 (5) ◽  
pp. 677-684 ◽  
Author(s):  
I Flechtner ◽  
K Lambot-Juhan ◽  
R Teissier ◽  
A Colmenares ◽  
G Baujat ◽  
...  
Keyword(s):  
Short Stature ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Comparison Group ◽  
Final Height ◽  
Normal Growth ◽  
Idiopathic Short Stature ◽  
Skeletal Survey ◽  
Genetic Syndrome ◽  
The Impact

ObjectiveTo assess the prevalence of skeletal dysplasias (SDs) in patients with idiopathic short stature (ISS) or small for gestational age (SGA) status.SettingRare Endocrine/Growth Diseases Center in Paris, France.DesignA prospective study on consecutive patients with ISS and SGA enrolled from 2004 to 2009.MethodWe used a standardized workup to classify patients into well-established diagnostic categories. Of 713 patients with ISS (n=417) or SGA status (n=296), 50.9% underwent a skeletal survey. We chose patients labeled normal or with a prepubertal slowdown of growth as a comparison group.ResultsDiagnoses were ISS (16.9%), SGA (13.5%), normal growth (24.5%), transient growth rate slowing (17.3%), endocrine dysfunction (12%), genetic syndrome (8.9%), chronic disease (5.1%), and known SD (1.8%). SD was found in 20.9% of SGA and 21.8% ISS patients and in only 13.2% in our comparison group. SD prevalence was significantly higher in the ISS group than in the comparison group, especially (50%) for patients having at least one parent whose height was <−2 SDS. Dyschondrosteosis and hypochondroplasia were the most frequently identified SD, and genetic anomaly was found in 61.5 and 30% respectively. Subtle SD was found equally in the three groups and require long-term growth follow-up to evaluate the impact on final height.ConclusionSD may explain more than 20% of cases of growth retardation ascribed to ISS or SGA, and this proportion is higher when parental height is <−2 SDS. A skeletal survey should be obtained in patients with delayed growth in a context of ISS or SGA.

Sign in / Sign up

Export Citation Format

Share Document